

ACT Onco[®] + Report

| PATIENT | | |
|------------------------------------|---|----------------------|
| Identifier: 蔡坐娜 | | Patient ID: 23621514 |
| Date of Birth: Jan 12, 1966 | | Gender: Female |
| Diagnosis: Lung adenocarcinoma | | |
| ORDERING PHYSICIAN | | |
| Name: 陳育民醫師 | | Tel: 886-228712121 |
| Facility: 臺北榮總 | | |
| Address: 臺北市北投區石牌路二段 201 號 | | |
| SPECIMEN | | |
| Specimen ID: S11211070A/S11211071B | Collection site: Tissue, left neck lymph node | Type: FFPE tissue |
| Date received: Mar 17, 2023 | Lab ID: AA-23-01629/AA-23-01630 | D/ID: NA |

ABOUT ACT Onco[®]+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) (≤ 15 nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

SUMMARY FOR ACTIONABLE VARIANTS

VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

| Genomic Alterations/Biomarkers | Probable Effects in Patient's Cancer Type | | Probable Sensitive in Other Cancer Types |
|--------------------------------|--|---|--|
| | Sensitive | Resistant | |
| EGFR L858R | Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib | - | - |
| EGFR T790M | Osimertinib | Afatinib, Dacomitinib, Erlotinib, Gefitinib | - |

VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

| Genomic Alterations/Biomarkers | Possibly Sensitive | Possibly Resistant |
|--------------------------------|--------------------|--------------------|
| | Not detected | |

Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criteria for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

ACTOnco® + Report

TESTING RESULTS

VARIANT(S) WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

| Gene | Amino Acid Change | Allele Frequency |
|------|-------------------|------------------|
| EGFR | T790M | 22.1% |
| EGFR | L858R | 20.5% |

- Copy Number Alterations

| Chromosome | Gene | Variation | Copy Number |
|------------|--------|-----------------------|-------------|
| Chr13 | BRCA2 | Heterozygous deletion | 1 |
| Chr15 | RAD51 | Heterozygous deletion | 1 |
| Chr5 | RAD50 | Heterozygous deletion | 1 |
| Chr9 | CDKN2A | Heterozygous deletion | 1 |

- Fusions

| Fusion Gene & Exon | Transcript ID |
|--|---------------|
| No fusion gene detected in this sample | |

- Immune Checkpoint Inhibitor (ICI) Related Biomarkers

| Biomarker | Results |
|----------------------------------|-----------------------------|
| Tumor Mutational Burden (TMB) | 1.9 muts/Mb |
| Microsatellite Instability (MSI) | Microsatellite stable (MSS) |

Note:

- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 36% tumor purity.
- For more therapeutic agents which are possibly respond to heterozygous deletion of genes listed above, please refer to APPENDIX for more information.
- TMB was calculated by using the sequenced regions of ACTOnco® to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at ≥ 7.5 mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is $< 30\%$.

ACT Onco[®] + Report

THERAPEUTIC IMPLICATIONS TARGETED THERAPIES

| Genomic Alterations | Therapies | Effect |
|---------------------|--|------------------|
| Level 1 | | |
| EGFR L858R | Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib | sensitive |
| EGFR T790M | Osimertinib | sensitive |
| Level 2 | | |
| EGFR T790M | Afatinib, Dacomitinib, Erlotinib, Gefitinib | resistant |

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

| Level | Description |
|-----------|--|
| 1 | FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication |
| 2 | Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication |
| 3A | Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type |
| 3B | Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required) |
| 4 | Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies |

ACT Onco[®] + Report

IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

- Other Biomarkers with Potential Clinical Effects for ICIs

| Genomic Alterations | Potential Clinical Effects |
|---------------------|---|
| EGFR aberration | Likely associated with WORSE response to ICIs |

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

OTHERS

Pharmacogenomic implication

| Gene | Detection Site | Genotype | Drug Impact | Level of Evidence* |
|--------|----------------|----------|---------------------------|--------------------|
| UGT1A1 | rs4148323 | AG | Irinotecan-based regimens | Level 1B |

Clinical Interpretation:

Patients with the AG genotype and cancer who are treated with irinotecan-based regimens may have an increased risk of diarrhea and neutropenia as compared to patients with the GG genotype, or a decreased risk of diarrhea and neutropenia compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of diarrhea and neutropenia.

* Level of evidence was defined by PharmGKB (<https://www.pharmgkb.org/page/clinAnnLevels>)

Level 1A: Clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation.

Level 1B: Clinical annotations describe variant-drug combinations with a high level of evidence supporting the association but no variant-specific prescribing guidance in an annotated clinical guideline or FDA drug label.

Level 2A: Variants in Level 2A clinical annotations are found in PharmGKB's Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely.

Note:

Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

ACT Onco[®] + Report

VARIANT INTERPRETATION

EGFR L858R, T790M

Biological Impact

The EGFR gene encodes for the Epidermal Growth Factor Receptor, a receptor tyrosine kinase which binds to its ligands, including Epidermal Growth Factor (EGF) and Transforming Growth Factor- α (TGF- α), activates downstream signaling pathways, including the canonical oncogenic MAPK and PI3K/AKT/mTOR signaling cascades^[1]. Increased EGFR activity by mutations and/or amplification of the EGFR gene has been described in a wide range of cancers, such as lung, brain, colorectal and head and neck cancer^[2]. Mutations in the kinase domain of EGFR are commonly observed in non-small cell lung cancer (NSCLC), resulting in a constitutively activated form of the receptor^[3]. On the other hand, in the brain and colorectal cancers, the most prevalent EGFR alteration is copy number amplification that results in receptor overexpression^[4].

EGFR L858R is a missense mutation at position 858, located in exon 21, which encodes part of the kinase domain, from a leucine to an arginine residue^[5]. The two most common EGFR alterations, L858R mutation and exon 19 deletions can result in constitutive activation of signal transduction pathways, leading to cell proliferation or anti-apoptosis without ligand binding^[6].

EGFR T790M lies within the ATP-binding pocket of EGFR and is a gatekeeper mutation^[7]. T790M is a common secondary somatic mutation that results in increased EGFR kinase activity and resistance to reversible tyrosine kinase inhibitors^{[7][8]}. Several studies also reported the T790M mutation of the pretreatment specimens with EGFR mutations using different methods and sample types^{[9][10][11]}.

Therapeutic and prognostic relevance

There is accumulated clinical evidence suggested that patients with MDM2/MDM4 amplification or EGFR aberrations exhibited poor clinical outcome and demonstrated a significantly increased rate of tumor growth (hyper-progression) after receiving immune checkpoint (PD-1/PD-L1) inhibitors therapies^[12] (Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376).

The first- and second-generation EGFR-TKIs, including dacomitinib, erlotinib, gefitinib, and afatinib, have been approved by the U.S. FDA as first-line treatments for non-small cell lung cancer patients with EGFR exon 19 deletion or L858R mutation. Osimertinib, a third-generation EGFR-TKI, has also been approved by the U.S. FDA. It is indicated for adjuvant treatment or first-line treatment of metastatic NSCLC patients with EGFR exon 19 deletion or L858R mutation.

A phase III trial (NCT01774721) show that dacomitinib significantly improved PFS over gefitinib in first-line treatment of patients with EGFR-mutation-positive NSCLC^[13]. Another phase III trial (NCT00949650) demonstrated that median PFS among lung cancer patients with exon 19 deletion or L858R EGFR mutation (n=308) was 13.6 months for afatinib and 6.9 months for chemotherapy^[14]. Results from a double-blind, phase 3 trial further showed that osimertinib significantly demonstrated longer PFS than standard EGFR-TKIs (18.9 months vs. 10.2 months) in previously untreated EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC^[15].

Osimertinib has also been approved by the U.S. FDA for Treatment of adult patients with metastatic NSCLC whose tumors have EGFR T790M mutation and have progressed on or after EGFR-TKI therapy.

The EGFR T790M mutation has been demonstrated to confer resistance to TKIs (dacomitinib, gefitinib, erlotinib, and afatinib) in preclinical and clinical studies^{[16][17][18][19]}.

ACT Onco[®] + Report

BRCA2 Heterozygous deletion

Biological Impact

The BRCA2 gene encodes a tumor suppressor involved in the homologous recombination pathway for double-strand DNA repair^[20]. BRCA2 has been implicated as a haploinsufficient gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions^[21]. BRCA2 germline mutations confer an increased lifetime risk of developing breast, ovarian, prostate and pancreatic cancer, limited reports of related gastric cancer, and Fanconi anemia subtype D1-associated risk of brain cancer, medulloblastoma, pharyngeal cancer, chronic lymphocytic leukemia and acute myeloid leukemia^[22]. Somatic mutations in BRCA2 are highest in colorectal, non-small cell lung cancer (NSCLC), and ovarian cancers^[23].

Therapeutic and prognostic relevance

Multiple PARP inhibitors, including olaparib, rucaparib, niraparib, and talazoparib, have been approved by the U.S. FDA for the treatment of cancer. Olaparib is approved for multiple settings in advanced ovarian cancer, metastatic breast cancer with BRCA mutations, metastatic pancreatic cancer, and mCRPC with HRR gene mutations, including BRCA mutations. Rucaparib is approved for maintenance treatment of recurrent ovarian cancer with BRCA mutations and mCRPC with BRCA mutations. Niraparib is approved for maintenance treatment of advanced ovarian cancer and recurrent ovarian cancer with BRCA mutations. Talazoparib is approved for locally advanced or metastatic breast cancer with BRCA mutations.

According to the NCCN guidelines, rucaparib is recommended as recurrence therapy for patients with BRCA-mutated ovarian cancer who have been treated with multiple lines of chemotherapy. It is also recommended as maintenance therapy for patients with metastatic pancreatic cancer who have undergone prior platinum-based therapy and harbor germline or somatic BRCA mutations. Additionally, niraparib is recommended as maintenance therapy for ovarian cancer patients with BRCA mutations.

CDKN2A Heterozygous deletion

Biological Impact

The Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) gene encodes the p16 (p16INK4a) and p14 (ARF) proteins. p16INK4a binds to CDK4 and CDK6, inhibiting these CDKs from binding D-type cyclins and phosphorylating the retinoblastoma (RB) protein whereas p14 (ARF) blocks the oncogenic activity of MDM2 by inhibiting MDM2-induced degradation of p53^{[24][25][26]}. CDKN2A has been reported as a haploinsufficient tumor suppressor with one copy loss that may lead to weak protein expression and is insufficient to execute its original physiological functions^[27]. Loss of CDKN2A has been frequently found in human tumors that result in uncontrolled cell proliferation^{[28][29]}.

Therapeutic and prognostic relevance

Intact p16-Cdk4-Rb axis is known to be associated with sensitivity to cyclin-dependent kinase inhibitors^{[30][31]}. Several case reports also revealed that patients with CDKN2A-deleted tumors respond to the CDK4/6-specific inhibitor treatments^{[32][33][34]}. However, there are clinical studies that demonstrated CDKN2A nuclear expression, CDKN2A/CDKN2B co-deletion, or CDKN2A inactivating mutation was not associated with clinical benefit from CDK4/6 inhibitors, such as palbociclib and ribociclib, in RB-positive patients^{[35][36][37]}. However, CDKN2A loss or mutation has been determined as an inclusion criterion for the trial evaluating CDK4/6 inhibitors efficacy in different types of solid tumors (NCT02693535, NCT02187783).

The phase II TAPUR trial demonstrated clinical benefits to palbociclib monotherapy in advanced NSCLC or head and neck cancer harboring a CDKN2A mutation or copy number loss. However, pancreatic and biliary cancer patients harboring a CDKN2A mutation or copy number loss did not demonstrate an objective response or stable disease when treated with palbociclib monotherapy for 16 weeks (DOI: 10.1200/JCO.2021.39.15_suppl.6043)^{[38][39]}.

ACT Onco[®] + Report

Notably, the addition of several CDK4/6 inhibitors to hormone therapies, including palbociclib in combination with letrozole, ribociclib plus letrozole, and abemaciclib combines with fulvestrant, have been approved by the U.S. FDA for the treatment of ER+ and HER2- breast cancer^{[31][40][41]}.

In a Phase I trial, a KRAS wild-type squamous non-small cell lung cancer (NSCLC) patient with CDKN2A loss had a partial response when treated with CDK4/6 inhibitor abemaciclib^[33]. Administration of combined palbociclib and MEK inhibitor PD-0325901 yield promising progression-free survival among patients with KRAS mutant non-small cell lung cancer (NSCLC) (AACR 2017, Abstract CT046). Moreover, MEK inhibitor in combination with CDK4/6 inhibitor demonstrates significant anti-KRAS-mutant NSCLC activity and radiosensitizing effect in preclinical models^[42].

A retrospective analysis demonstrated that concurrent deletion of CDKN2A with EGFR mutation in patients with non-small cell lung cancer (NSCLC), predicts worse overall survival after EGFR-TKI treatment^[43].

RAD50 Heterozygous deletion

Biological Impact

The RAD50 gene encodes a highly-conserved DNA double-strand break (DSB) repair factor. It forms MRN complex with NBS1 and MRE11 protein and is involved in sensing and early processing of DSB, cell cycle checkpoints, DNA recombination and maintenance of telomeres^{[44][45]}. Mutations in the components of the MRN complex could increase susceptibility to familial breast cancer^{[46][47]}, gastric cancer^[48], colorectal cancer^[49], and urothelial cancer^[50]. RAD50 has been implicated as a haploinsufficient gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions^[51]. Besides, RAD50 deletion was also suggested as a marker of BRCAness, a phenotype shared between non-BRCA1/2-mutated ovarian cancers and BRCA1/2-mutated ovarian cancers^[52].

Therapeutic and prognostic relevance

Preclinical data showed that knockdown of the RAD50 gene in ovarian cancer cell lines was significantly associated with better responses to two PARP inhibitors, olaparib and rucaparib^[52]. RAD50 has been selected as an inclusion criterion for the trials examining talazoparib efficacy in HER2-negative breast cancer, olaparib efficacy in breast cancer, rucaparib efficacy in metastatic prostate cancer and niraparib efficacy in any malignancy (except prostate) (NCT02401347, NCT03207347, NCT03344965, NCT03413995).

RAD51 Heterozygous deletion

Biological Impact

The RAD51 gene encodes a recombinase that is crucial for homologous recombination (HR)-mediated repair of double-strand DNA breaks (DSBs) by forming complexes with known tumor suppressors including BRCA1, BRCA2, and PALB2^{[53][54][55]}. RAD51 has been characterized as a haploinsufficient tumor suppressor gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions^[56]. Overexpression of RAD51 has been observed in many cancer cells, including pancreatic cancer and breast cancer and its hyperexpression is implicated in drug resistance^{[57][58][59][60][61][62][63]}. Germline mutations in RAD51 are associated with increased susceptibility to breast cancer^{[64][65][66][67]}.

Therapeutic and prognostic relevance

RAD51 loss of function mutation has been determined as an inclusion criterion for the trial evaluating olaparib efficacy in ovarian cancer^[68]; rucaparib efficacy in solid tumor (NCT04171700); talazoparib efficacy in lung cancer (NCT03377556); niraparib efficacy in pancreatic cancer (NCT03553004) or any malignancy (except prostate cancer) (NCT03207347). Preclinical studies showed that decreased RAD51 expression could sensitize cells to olaparib-induced tumor cell cytotoxicity^{[69][70]}.

ACT Onco® + Report

US FDA-APPROVED DRUG(S)

Abemaciclib (VERZENIO)

Abemaciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Abemaciclib is developed and marketed by Eli Lilly under the trade name VERZENIO.

- FDA Approval Summary of Abemaciclib (VERZENIO)

| | |
|--|---|
| MONARCH E NCT03155997 | Breast cancer (Approved on 2021/10/12) |
| | HR+/HER2- Abemaciclib + tamoxifen/aromatase inhibitor vs. Tamoxifen/aromatase inhibitor [IDFS at 36 months(%): 86.1 vs. 79.0] |
| MONARCH 3^[71] NCT02246621 | Breast cancer (Approved on 2018/02/26) |
| | HR+/HER2- Abemaciclib + anastrozole/letrozole vs. Placebo + anastrozole/letrozole [PFS(M): 28.2 vs. 14.8] |
| MONARCH 2^[41] NCT02107703 | Breast cancer (Approved on 2017/09/28) |
| | HR+/HER2- Abemaciclib + fulvestrant vs. Placebo + fulvestrant [PFS(M): 16.4 vs. 9.3] |
| MONARCH 1^[72] NCT02102490 | Breast cancer (Approved on 2017/09/28) |
| | HR+/HER2- Abemaciclib [ORR(%): 19.7 vs. 17.4] |

Afatinib (GILOTRIF)

Afatinib acts as an irreversible covalent inhibitor of the ErbB family of receptor tyrosine kinases, including epidermal growth factor receptor (EGFR) and erbB-2 (HER2). Afatinib is developed and marketed by Boehringer Ingelheim under the trade name GILOTRIF (United States) and GIOTRIF (Europe).

- FDA Approval Summary of Afatinib (GILOTRIF)

| | |
|---|--|
| LUX-Lung 8^[73] NCT01523587 | Non-small cell lung carcinoma (Approved on 2016/04/15) |
| | EGFR ex19del or L858R Afatinib vs. Erlotinib [PFS(M): 2.4 vs. 1.9] |
| LUX-Lung 3^[74] NCT00949650 | Non-small cell lung carcinoma (Approved on 2013/07/13) |
| | EGFR ex19del or L858R Afatinib vs. Pemetrexed + cisplatin [PFS(M): 11.1 vs. 6.9] |

Dacomitinib (VIZIMPRO)

Dacomitinib is an oral kinase inhibitor that targets EGFR. Dacomitinib is developed and marketed by Pfizer under the trade name VIZIMPRO.

- FDA Approval Summary of Dacomitinib (VIZIMPRO)

| | |
|--|--|
| ARCHER 1050^[13] NCT01774721 | Non-small cell lung carcinoma (Approved on 2018/09/27) |
| | EGFR ex19del or L858R Dacomitinib vs. Gefitinib [PFS(M): 14.7 vs. 9.2] |

ACT Onco[®] + Report

Erlotinib (TARCEVA)

Erlotinib is a small molecule, reversible inhibitor of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase. Erlotinib is developed by OSI Pharmaceuticals, Genentech and Roche, and marketed by Astellas Pharm Global Development under the trade name TARCEVA.

- FDA Approval Summary of Erlotinib (TARCEVA)

| | |
|---|---|
| RELAY NCT02411448 | Non-small cell lung carcinoma (Approved on 2020/05/29) |
| | EGFR ex19del or L858R Erlotinib + ramucirumab vs. Erlotinib + placebo [PFS(M): 19.4 vs. 12.4] |
| EURTAC^[75] NCT00446225 | Non-small cell lung carcinoma (Approved on 2013/05/14) |
| | EGFR ex19del or L858R Erlotinib vs. Cisplatin + gemcitabine or cisplatin + docetaxel or carboplatin + gemcitabine or carboplatin + docetaxel [PFS(M): 10.4 vs. 5.2] |
| PA.3^[76] NCT00026338 | Pancreatic cancer (Approved on 2005/11/02) |
| | - Gemcitabine vs. Placebo [OS(M): 6.4 vs. 6] |

Gefitinib (IRESSA)

Gefitinib is a small molecule inhibitor of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase. Gefitinib is developed and marketed by AstraZeneca under the trade name IRESSA.

- FDA Approval Summary of Gefitinib (IRESSA)

| | |
|---|---|
| IFUM^[77] NCT01203917 | Non-small cell lung carcinoma (Approved on 2015/07/13) |
| | EGFR ex19del or L858R Gefitinib [ORR(%): 50.0] |

Niraparib (ZEJULA)

Niraparib is an oral, small molecule inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1 and -2 (PARP-1, -2). Niraparib is developed and marketed by Tesaro under the trade name ZEJULA.

- FDA Approval Summary of Niraparib (ZEJULA)

| | |
|---|---|
| PRIMA NCT02655016 | Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2020/04/29) |
| | - Niraparib vs. Placebo [PFS (overall population)(M): 13.8 vs. 8.2] |
| NOVA^[78] NCT01847274 | Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2017/03/27) |
| | - Niraparib vs. Placebo [PFS (overall population)(M): 11.3 vs. 4.7] |

ACT Onco[®] + Report

Olaparib (LYNPARZA)

Olaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase-1, -2, and -3 (PARP-1, -2, -3). Olaparib is developed by KuDOS Pharmaceuticals and marketed by AstraZeneca under the trade name LYNPARZA.

- FDA Approval Summary of Olaparib (LYNPARZA)

| | |
|---|---|
| Olympia NCT02032823 | Her2-negative high-risk early breast cancer (Approved on 2022/03/11) |
| | HER2-/gBRCA mutation Olaparib vs. Placebo [invasive disease-free survival (IDFS)(M):] |
| PROfound ^[79] NCT02987543 | Prostate cancer (Approved on 2020/05/19) |
| | HRR genes mutation Olaparib vs. Enzalutamide or abiraterone acetate [PFS(M): 5.8 vs. 3.5] |
| PAOLA-1 ^[80] NCT02477644 | Ovarian cancer (Approved on 2020/05/08) |
| | HRD+ Olaparib + bevacizumab vs. Placebo + bevacizumab [PFS(M): 37.2 vs. 17.7] |
| POLO ^[81] NCT02184195 | Pancreatic adenocarcinoma (Approved on 2019/12/27) |
| | gBRCA mutation Olaparib vs. Placebo [ORR(%): 23.0 vs. 12.0, PFS(M): 7.4 vs. 3.8] |
| SOLO-1 ^[82] NCT01844986 | Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2018/12/19) |
| | gBRCA mutation or sBRCA mutation Olaparib vs. Placebo [PFS(M): NR vs. 13.8] |
| OlympiAD ^[83] NCT02000622 | Breast cancer (Approved on 2018/02/06) |
| | HER2-/gBRCA mutation Olaparib vs. Chemotherapy [PFS(M): 7 vs. 4.2] |
| SOLO-2/ENGOT-Ov21 ^[84] NCT01874353 | Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2017/08/17) |
| | gBRCA mutation Olaparib vs. Placebo [PFS(M): 19.1 vs. 5.5] |
| Study19 ^[85] NCT00753545 | Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2017/08/17) |
| | - Olaparib vs. Placebo [PFS(M): 8.4 vs. 4.8] |

Osimertinib (TAGRISSO)

Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) for patients with tumors harboring EGFR T790M mutation. Osimertinib is developed and marketed by AstraZeneca under the trade name TAGRISSO.

- FDA Approval Summary of Osimertinib (TAGRISSO)

| | |
|--|---|
| ADAURA NCT02511106 | Non-small cell lung carcinoma (Approved on 2020/12/18) |
| | EGFR ex19del or L858R Osimertinib vs. Placebo + adjuvant chemotherapy [DFS(M): NR vs. 19.6] |
| FLAURA ^[15] NCT02296125 | Non-small cell lung carcinoma (Approved on 2018/04/18) |
| | EGFR ex19del or L858R Osimertinib vs. Gefitinib or erlotinib [PFS(M): 18.9 vs. 10.2] |
| AURA3 ^[86] NCT02151981 | Non-small cell lung carcinoma (Approved on 2017/03/30) |
| | EGFR T790M Osimertinib vs. Chemotherapy [PFS(M): 10.1 vs. 4.4] |

ACT Onco[®] + Report

| | |
|---|---|
| AURA^[87] NCT01802632 | Non-small cell lung carcinoma (Approved on 2015/11/13) |
| | EGFR T790M |
| | Osimertinib [ORR(%): 59.0] |

Palbociclib (IBRANCE)

Palbociclib is an oral, cyclin-dependent kinase (CDK) inhibitor specifically targeting CDK4 and CDK6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Palbociclib is developed and marketed by Pfizer under the trade name IBRANCE.

- FDA Approval Summary of Palbociclib (IBRANCE)

| | |
|---|---|
| PALOMA-2^[88] NCT01740427 | Breast cancer (Approved on 2017/03/31) |
| | ER+/HER2- |
| | Palbociclib + letrozole vs. Placebo + letrozole [PFS(M): 24.8 vs. 14.5] |
| PALOMA-3^[89] NCT01942135 | Breast cancer (Approved on 2016/02/19) |
| | ER+/HER2- |
| | Palbociclib + fulvestrant vs. Placebo + fulvestrant [PFS(M): 9.5 vs. 4.6] |

Ribociclib (KISQALI)

Ribociclib is a cyclin-dependent kinase (CDK) inhibitor specifically targeting cyclin D1/CDK4 and cyclin D3/CDK6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Ribociclib is developed by Novartis and Astex Pharmaceuticals and marketed by Novartis under the trade name KISQALI.

- FDA Approval Summary of Ribociclib (KISQALI)

| | |
|--|--|
| MONALEESA-2^[40] NCT01958021 | Breast cancer (Approved on 2017/03/13) |
| | HR+/HER2- |
| | Ribociclib vs. Letrozole [PFS(M): NR vs. 14.7] |

Rucaparib (RUBRACA)

Rucaparib is an inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1, -2 and -3 (PARP-1, -2, -3). Rucaparib is developed and marketed by Clovis Oncology under the trade name RUBRACA.

- FDA Approval Summary of Rucaparib (RUBRACA)

| | |
|---|--|
| TRITON2 NCT02952534 | Prostate cancer (Approved on 2020/05/15) |
| | gBRCA mutation or sBRCA mutation |
| | Rucaparib [ORR(%): 44.0, DOR(M): NE] |
| ARIEL3^[90] NCT01968213 | Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2018/04/06) |
| | - |
| | Rucaparib vs. Placebo [PFS (All)(M): 10.8 vs. 5.4, PFS (HRD)(M): 13.6 vs. 5.4, PFS (tBRCA)(M): 16.6 vs. 5.4] |

ACT Onco[®] + Report

Talazoparib (TALZENNA)

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2. Talazoparib is developed and marketed by Pfizer under the trade name TALZENNA.

- FDA Approval Summary of Talazoparib (TALZENNA)

| | |
|--|--|
| EMBRACA ^[91] NCT01945775 | Breast cancer (Approved on 2018/10/16) |
| | HER2-/gBRCA mutation |
| | Talazoparib vs. Chemotherapy [PFS(M): 8.6 vs. 5.6] |

D=day; W=week; M=month

ACT Onco[®] + Report

ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit <https://clinicaltrials.gov> to search and view for a complete list of open available and updated matched trials.

No trial has been found.

ACT Onco[®] + Report


SUPPLEMENTARY INFORMATION OF TESTING RESULTS DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

| Gene | Amino Acid Change | Exon | cDNA Change | Accession Number | COSMIC ID | Allele Frequency | Coverage |
|------|-------------------|------|-------------|------------------|-----------|------------------|----------|
| EGFR | L858R | 21 | c.2573T>G | NM_005228 | COSM6224 | 20.5% | 3967 |
| EGFR | T790M | 20 | c.2369C>T | NM_005228 | COSM6240 | 22.1% | 1548 |

- Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



ACT Onco[®] + Report

OTHER DETECTED VARIANTS

| Gene | Amino Acid Change | Exon | cDNA Change | Accession Number | COSMIC ID | Allele Frequency | Coverage |
|--------------|-----------------------|------|-------------------------|------------------|-------------|------------------|----------|
| APC | D1318_V1320 delinsEEK | 16 | c.3954_3959delinsAGAAAA | NM_000038 | - | 11.7% | 1069 |
| EGFR | V651L | 17 | c.1951G>T | NM_005228 | - | 20.6% | 2957 |
| FGFR3 | R158Q | 5 | c.473G>A | NM_000142 | COSM6937676 | 48.7% | 876 |
| GATA2 | S73R | 2 | c.219C>G | NM_032638 | - | 48.1% | 1490 |
| KDM6A | Splice region | - | c.3433+4A>G | NM_021140 | - | 20.8% | 4000 |
| PDCD1 (PD-1) | G201_A202dup | 4 | c.601_606dup | NM_005018 | COSM4615682 | 47.5% | 859 |



Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

ACTOnco® + Report

TEST DETAILS

SPECIMEN RECEIVED AND PATHOLOGY REVIEW



- Collection date: Mar 14, 2023
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11211070A/S11211071B
- Collection site: Tissue, left neck lymph node
- Examined by: Dr. Chien-Ta Chiang
 1. The percentage of viable tumor cells in total cells in the whole slide (%): 20%/30%
 2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 35%/30%
 3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%/0%
 4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%/0%
 5. Additional comment: NA
- Manual macrodissection: Performed on the highlighted region/Not performed
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

RUN QC

- Panel: ACTOnco®+

DNA test

- Mean Depth: 1901x
- Target Base Coverage at 100x: 96%

RNA test

- Average unique RNA Start Sites per control GSP2: 163

ACTOnco[®] + Report

LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

NEXT-GENERATION SEQUENCING (NGS) METHODS

DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage ≥ 20 , allele frequency $\geq 5\%$ and actionable variants with allele frequency $\geq 2\%$ were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at $100\times \geq 85\%$ with a mean coverage $\geq 500\times$.

Variants reported in Genome Aggregation database with $> 1\%$ minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:

Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation ≥ 0.3 were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco[®] to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to ≥ 7.5 mutations per megabase (Muts/Mb); TMB-Low corresponds to < 7.5 Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is $< 30\%$.

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in > 400 genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be ≥ 10 .

ACT Onco[®] + Report

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2 ≥ 3 ; (2) Number of supporting reads spanning the fusion junction ≥ 5 ; (3) Percentage of supporting reads spanning the fusion junction $\geq 10\%$; (4) Fusions annotated in Quiver Gene Fusion Database.

DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

Variant Analysis:

醫檢師陳韻仔 博士
Yun-Yu Chen Ph.D.
檢字第 015647 號

Yun Yu Chen

Sign Off

解剖病理專科醫師王業翰
Yeh-Han Wang M.D.
病解字第 000545 號

Yeh

ACT Onco[®] + Report

GENE LIST SNV & CNV

| | | | | | | | | | | | |
|----------|---------|---------|----------|----------|---------|-----------|-----------|----------|----------|----------|----------|
| ABCB1* | ABCC2* | ABCG2* | ABL1 | ABL2 | ADAMTS1 | ADAMTS13 | ADAMTS15 | ADAMTS16 | ADAMTS18 | ADAMTS6 | ADAMTS9 |
| ADAMTSL1 | ADGRA2 | ADH1C* | AKT1 | AKT2 | AKT3 | ALDH1A1* | ALK | AMER1 | APC | AR | ARAF |
| ARID1A | ARID1B | ARID2 | ASXL1 | ATM | ATR | ATRX | AURKA | AURKB | AXIN1 | AXIN2 | AXL |
| B2M | BAP1 | BARD1 | BCL10 | BCL2* | BCL2L1 | BCL2L2* | BCL6 | BCL9 | BCOR | BIRC2 | BIRC3 |
| BLM | BMPR1A | BRAF | BRCA1 | BRCA2 | BRD4 | BRIP1 | BTG1 | BTG2* | BTB | BUB1B | CALR |
| CANX | CARD11 | CASP8 | CBFB | CBL | CCNA1 | CCNA | CCNB1 | CCNB2 | CCNB3 | CCND1 | CCND2 |
| CCND3 | CCNE1 | CCNE2 | CCNH | CD19 | CD274 | CD58 | CD70* | CD79A | CD79B | CDC73 | CDH1 |
| CDK1 | CDK12 | CDK2 | CDK4 | CDK5 | CDK6 | CDK7 | CDK8 | CDK9 | CDKN1A | CDKN1B | CDKN2A |
| CDKN2B | CDKN2C | CEBPA* | CHEK1 | CHEK2 | CIC | CREBBP | CRKL | CRLF2 | CSF1R | CTCF | CTLA4 |
| CTNNA1 | CTNNB1 | CUL3 | CYLD | CYP1A1* | CYP2B6* | CYP2C19* | CYP2C8* | CYP2D6 | CYP2E1* | CYP3A4* | CYP3A5* |
| DAXX | DCUN1D1 | DDR2 | DICER1 | DNMT3A | DOT1L | DPYD | DTX1 | E2F3 | EGFR | EP300 | EPCAM |
| EPHA2 | EPHA3 | EPHA5 | EPHA7 | EPHB1 | ERBB2 | ERBB3 | ERBB4 | ERCC1 | ERCC2 | ERCC3 | ERCC4 |
| ERCC5 | ERG | ESR1 | ESR2 | ETV1 | ETV4 | EZH2 | FAM46C | FANCA | FANCC | FANCD2 | FANCE |
| FANCF | FANCG | FANCL | FAS | FAT1 | FBXW7 | FCGR2B | FGF1* | FGF10 | FGF14 | FGF19* | FGF23 |
| FGF3 | FGF4* | FGF6 | FGFR1 | FGFR2 | FGFR3 | FGFR4 | FH | FLCN | FLT1 | FLT3 | FLT4 |
| FOXL2* | FOXP1 | FRG1 | FUBP1 | GATA1 | GATA2 | GATA3 | GNA11 | GNA13 | GNAQ | GNAS | GREM1 |
| GRIN2A | GSK3B | GSTP1* | GSTT1* | HGF | HIF1A | HIST1H1C* | HIST1H1E* | HNF1A | HR | HRAS* | HSP90AA1 |
| HSP90AB1 | HSPA4 | HSPA5 | IDH1 | IDH2 | IFNL3* | IGF1 | IGF1R | IGF2 | IKBKB | IKBKE | IKZF1 |
| IL6 | IL7R | INPP4B | INSR | IRF4 | IRS1 | IRS2* | JAK1 | JAK2 | JAK3 | JUN* | KAT6A |
| KDM5A | KDM5C | KDM6A | KDR | KEAP1 | KIT | KMT2A | KMT2C | KMT2D | KRAS | LCK | LIG1 |
| LIG3 | LMO1 | LRP1B | LYN | MALT1 | MAP2K1 | MAP2K2 | MAP2K4 | MAP3K1 | MAP3K7 | MAPK1 | MAPK3 |
| MAX | MCL1 | MDM2 | MDM4 | MED12 | MEF2B | MEN1 | MET | MITF | MLH1 | MPL | MRE11 |
| MSH2 | MSH6 | MTHFR* | MTOR | MUC16 | MUC4 | MUC6 | MUTYH | MYC | MYCL | MYCN | MYD88 |
| NAT2* | NBN | NEFH | NF1 | NF2 | NFE2L2 | NFKB1 | NFKBIA | NKX2-1* | NOTCH1 | NOTCH2 | NOTCH3 |
| NOTCH4 | NPM1 | NQO1* | NRAS | NSD1 | NTRK1 | NTRK2 | NTRK3 | PAK3 | PALB2 | PARP1 | PAX5 |
| PAX8 | PBRM1 | PDCD1 | PDCD1LG2 | PDGFRA | PDGFRB | PDIA3 | PGF | PHOX2B* | PIK3C2B | PIK3C2G | PIK3C3 |
| PIK3CA | PIK3CB | PIK3CD | PIK3CG | PIK3R1 | PIK3R2 | PIK3R3 | PIM1 | PMS1 | PMS2 | POLB | POLD1 |
| POLE | PPARG | PPP2R1A | PRDM1 | PRKAR1A | PRKCA | PRKCB | PRKCG | PRKCI | PRKCQ | PRKDC | PRKN |
| PSMB8 | PSMB9 | PSME1 | PSME2 | PSME3 | PTCH1 | PTEN | PTGS2 | PTPN11 | PTPRD | PTPRT | RAC1 |
| RAD50 | RAD51 | RAD51B | RAD51C | RAD51D | RAD52 | RAD54L | RAF1 | RARA | RB1 | RBM10 | RECQL4 |
| REL | RET | RHOA | RICTOR | RNF43 | ROS1 | RPPH1 | RPTOR | RUNX1 | RUNX1T1 | RXRA | SDHA |
| SDHB | SDHC | SDHD | SERPINB3 | SERPINB4 | SETD2 | SF3B1 | SGK1 | SH2D1A* | SLC19A1* | SLC22A2* | SLC1B1* |
| SLC1B3* | SMAD2 | SMAD3 | SMAD4 | SMARCA4 | SMARCB1 | SMO | SOC1* | SOX2* | SOX9 | SPEN | SPOP |
| SRC | STAG2 | STAT3 | STK11 | SUFU | SYK | SYNE1 | TAF1 | TAP1 | TAP2 | TAPBP | TBX3 |
| TEK | TERT | TET1 | TET2 | TGFBR2 | TMSB4X* | TNF | TNFAIP3 | TNFRSF14 | TNFSF11 | TOP1 | TP53 |
| TPMT* | TSC1 | TSC2 | TSHR | TYMS | U2AF1 | UBE2A* | UBE2K | UBR5 | UGT1A1* | USH2A | VDR* |
| VEGFA | VEGFB | VHL | WT1 | XIAP | XPO1 | XRCC2 | ZNF217 | | | | |

*Analysis of copy number alterations NOT available.

FUSION

| | | | | | | | | | | | | |
|-----|------|------|-------|-------|-------|-----|------|-------|-------|-------|-----|------|
| ALK | BRAF | EGFR | FGFR1 | FGFR2 | FGFR3 | MET | NRG1 | NTRK1 | NTRK2 | NTRK3 | RET | ROS1 |
|-----|------|------|-------|-------|-------|-----|------|-------|-------|-------|-----|------|


ACT Onco[®] + Report

APPENDIX

POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

| Gene | Therapies | Possible effect |
|---------------|---|------------------|
| <i>CDKN2A</i> | Abemaciclib, Palbociclib, Ribociclib | sensitive |
| <i>BRCA2</i> | Niraparib, Olaparib, Rucaparib, Talazoparib | sensitive |
| <i>RAD50</i> | Niraparib, Olaparib, Rucaparib, Talazoparib | sensitive |
| <i>RAD51</i> | Niraparib, Olaparib, Rucaparib, Talazoparib | sensitive |


SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS



1: Abemaciclib, Palbociclib, Ribociclib


ACT Onco[®] + Report

Receptor Tyrosine Kinase/Growth Factor Signalling



1: Erlotinib, Afatinib, Gefitinib, Osimertinib, Dacomitinib; 2: Afatinib

DNA Repair System



1: Olaparib, Niraparib, Rucaparib, Talazoparib

ACT Onco® + Report

DISCLAIMER

法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。

本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

ACT Onco[®] + Report

REFERENCE

1. PMID: 18045542; 2007, Cell;131(5):1018
SnapShot: EGFR signaling pathway.
2. PMID: 10880430; 2000, EMBO J;19(13):3159-67
The ErbB signaling network: receptor heterodimerization in development and cancer.
3. PMID: 15329413; 2004, Proc Natl Acad Sci U S A;101(36):13306-11
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
4. PMID: 11426640; 2000, Oncogene;19(56):6550-65
The EGF receptor family as targets for cancer therapy.
5. PMID: 17318210; 2007, Nat Rev Cancer;7(3):169-81
Epidermal growth factor receptor mutations in lung cancer.
6. PMID: 22263017; 2010, J Thorac Dis;2(1):48-51
Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.
7. PMID: 20026433; 2010, Biochim Biophys Acta;1804(3):559-66
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.
8. PMID: 18227510; 2008, Proc Natl Acad Sci U S A;105(6):2070-5
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.
9. PMID: 28932544; 2017, J Thorac Dis;9(8):2397-2403
The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR.
10. PMID: 25882755; 2015, Clin Cancer Res;21(15):3552-60
Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.
11. PMID: 26015401; 2015, Oncotarget;6(24):20466-73
Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR.
12. PMID: 28351930; 2017, Clin Cancer Res;23(15):4242-4250
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
13. PMID: 28958502; 2017, Lancet Oncol;18(11):1454-1466
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
14. PMID: 29653820; 2018, Clin Lung Cancer;19(4):e465-e479
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
15. PMID: 29151359; 2018, N Engl J Med;378(2):113-125
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
16. PMID: 27912760; 2016, J Biomed Sci;23(1):86
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
17. PMID: 15728811; 2005, N Engl J Med;352(8):786-92
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
18. PMID: 26862733; 2016, Oncotarget;7(11):12404-13

ACT Onco[®] + Report

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.

19. PMID: 29410323; 2018, J Thorac Oncol;13(5):727-731
EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.
20. PMID: 11239455; 2001, Mol Cell;7(2):263-72
BRCA2 is required for homology-directed repair of chromosomal breaks.
21. PMID: 17597348; 2007, Ann Surg Oncol;14(9):2510-8
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
22. PMID: 22193408; 2011, Nat Rev Cancer;12(1):68-78
BRCA1 and BRCA2: different roles in a common pathway of genome protection.
23. PMID: 27283171; 2016, J Natl Compr Canc Netw;14(6):795-806
The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?
24. PMID: 17055429; 2006, Cell;127(2):265-75
The regulation of INK4/ARF in cancer and aging.
25. PMID: 8521522; 1995, Cell;83(6):993-1000
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.
26. PMID: 9529249; 1998, Cell;92(6):725-34
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.
27. PMID: 16115911; 2005, Clin Cancer Res;11(16):5740-7
Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype.
28. PMID: 7550353; 1995, Nat Genet;11(2):210-2
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.
29. PMID: 24089445; 2013, Clin Cancer Res;19(19):5320-8
The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
30. PMID: 27849562; 2017, Gut;66(7):1286-1296
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
31. PMID: 25524798; 2015, Lancet Oncol;16(1):25-35
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
32. PMID: 28283584; 2017, Oncologist;22(4):416-421
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.
33. PMID: 27217383; 2016, Cancer Discov;6(7):740-53
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
34. PMID: 26715889; 2015, Curr Oncol;22(6):e498-501
Does CDKN2A loss predict palbociclib benefit?
35. PMID: 25501126; 2015, Clin Cancer Res;21(5):995-1001
CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
36. PMID: 27542767; 2016, Clin Cancer Res;22(23):5696-5705
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.

ACT Onco[®] + Report

37. PMID: 24797823; 2014, Oncologist;19(6):616-22
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.
38. PMID: 35050752; 2020, JCO Precis Oncol;4():757-766
Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
39. PMID: 35100714; 2019, JCO Precis Oncol;3():1-8
Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
40. PMID: 27717303; 2016, N Engl J Med;375(18):1738-1748
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
41. PMID: 28580882; 2017, J Clin Oncol;35(25):2875-2884
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
42. PMID: 26728409; 2016, Clin Cancer Res;22(1):122-33
Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
43. PMID: 31401335; 2019, Transl Oncol;12(11):1425-1431
Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors.
44. PMID: 9315668; 1997, Mol Cell Biol;17(10):6087-96
hMre11 and hRad50 nuclear foci are induced during the normal cellular response to DNA double-strand breaks.
45. PMID: 16467875; 2006, Cell Res;16(1):45-54
The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control.
46. PMID: 16385572; 2006, Int J Cancer;118(11):2911-6
Evaluation of RAD50 in familial breast cancer predisposition.
47. PMID: 24894818; 2014, Breast Cancer Res;16(3):R58
Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
48. PMID: 18440592; 2008, Hum Pathol;39(6):925-32
Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival.
49. PMID: 11196187; 2001, Cancer Res;61(1):36-8
Frameshift mutations at coding mononucleotide repeats of the hRAD50 gene in gastrointestinal carcinomas with microsatellite instability.
50. PMID: 24934408; 2014, Cancer Discov;4(9):1014-21
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.
51. PMID: 16474176; 2006, Carcinogenesis;27(8):1593-9
RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability.
52. PMID: 27016230; 2016, Gynecol Oncol;141(1):57-64
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
53. PMID: 20930833; 2010, Nature;467(7316):667-8
DNA repair: A protein giant in its entirety.
54. PMID: 20729858; 2010, Nat Struct Mol Biol;17(10):1263-5
The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA.

ACT Onco[®] + Report

55. PMID: 20729832; 2010, Nature;467(7316):678-83
Purified human BRCA2 stimulates RAD51-mediated recombination.
56. PMID: 22305526; 2012, Am J Hum Genet;90(2):301-7
RAD51 haploinsufficiency causes congenital mirror movements in humans.
57. PMID: 18243065; 2008, DNA Repair (Amst);7(5):686-93
The consequences of Rad51 overexpression for normal and tumor cells.
58. PMID: 24811120; 2014, Oncotarget;5(10):3261-72
Rad51 supports triple negative breast cancer metastasis.
59. PMID: 26317153; 2015, Cell Cycle;14(19):3190-202
High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation.
60. PMID: 21807066; 2011, Biochim Biophys Acta;1816(2):209-18
RAD51 as a potential biomarker and therapeutic target for pancreatic cancer.
61. PMID: 10851081; 2000, Oncogene;19(23):2791-5
DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma.
62. PMID: 24741789; 2014, Rev Med Chir Soc Med Nat Iasi;118(1):133-40
Rad51 overexpression and resistance to genotoxic agents. A study in the fission yeast Schizosaccharomyces pombe.
63. PMID: 18618591; 2009, Mol Carcinog;48(2):105-9
Rad51 overexpression rescues radiation resistance in BRCA2-defective cancer cells.
64. PMID: 10807537; 2000, J Hum Genet;45(3):133-7
Identification of Rad51 alteration in patients with bilateral breast cancer.
65. PMID: 26108708; 2015, Sci Rep;5():11588
RAD51 135G>C substitution increases breast cancer risk in an ethnic-specific manner: a meta-analysis on 21,236 cases and 19,407 controls.
66. PMID: 11248061; 2001, Proc Natl Acad Sci U S A;98(6):3232-6
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
67. PMID: 17999359; 2007, Am J Hum Genet;81(6):1186-200
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.
68. PMID: 30353044; 2018, Br J Cancer;119(11):1401-1409
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
69. PMID: 24577941; 2014, Mol Cancer Ther;13(5):1170-80
The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
70. PMID: 28759753; 2017, Biomed Pharmacother;94():165-168
Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib.
71. PMID: 28968163; 2017, J Clin Oncol;35(32):3638-3646
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
72. PMID: 28533223; 2017, Clin Cancer Res;23(17):5218-5224
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2-Metastatic Breast Cancer.
73. PMID: 26156651; 2015, Lancet Oncol;16(8):897-907
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

ACT Onco[®] + Report

74. PMID: 23816960; 2013, J Clin Oncol;31(27):3327-34
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
75. PMID: 22285168; 2012, Lancet Oncol;13(3):239-46
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EORTC): a multicentre, open-label, randomised phase 3 trial.
76. PMID: 17452677; 2007, J Clin Oncol;25(15):1960-6
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
77. PMID: 24263064; 2014, Br J Cancer;110(1):55-62
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
78. PMID: 27717299; 2016, N Engl J Med;375(22):2154-2164
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
79. PMID: 32343890; 2020, N Engl J Med;382(22):2091-2102
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
80. PMID: 31851799; 2019, N Engl J Med;381(25):2416-2428
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
81. PMID: 31157963; 2019, N Engl J Med;381(4):317-327
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
82. PMID: 30345884; 2018, N Engl J Med;379(26):2495-2505
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
83. PMID: 28578601; 2017, N Engl J Med;377(6):523-533
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
84. PMID: 28754483; 2017, Lancet Oncol;18(9):1274-1284
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
85. PMID: 27617661; 2016, Lancet Oncol;17(11):1579-1589
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
86. PMID: 27959700; 2017, N Engl J Med;376(7):629-640
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
87. PMID: 25923549; 2015, N Engl J Med;372(18):1689-99
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
88. PMID: 27959613; 2016, N Engl J Med;375(20):1925-1936
Palbociclib and Letrozole in Advanced Breast Cancer.
89. PMID: 26030518; 2015, N Engl J Med;373(3):209-19
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
90. PMID: 28916367; 2017, Lancet;390(10106):1949-1961
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

ACT Onco[®] + Report

91. PMID: 30110579; 2018, N Engl J Med;379(8):753-763
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.